Table 2.
The summarized table of the FGF21 analogs and the effect of the analogs on the body.
| Study groups | Hepatic fat content | Hepatic inflammation/ fibrosis | Blood tests | Body weight | Reference | FGF21 analog | |
|---|---|---|---|---|---|---|---|
| 1 | AFLD mice | Suppress hepatocyte lipid droplet accumulation | Decrease oxidative stress | Decreased TG, TChol, LDL | – | Zhu et al. (32) | Recombinant FGF21 |
| 2 | Alcohol-treated HepG2 cells | Reduced fat accumulation | Suppressed intracellular ROS products | – | – | Zhu et al. (32) | Recombinant FGF21 |
| 3 | Alcohol-fed Wild type mice | Decrease hepatic fat accumulation | Decrease inflammation | Reduced ALT, AST and plasma TG | – | Liu et al. (68) | Recombinant FGF21 (rhFGF21) |
| 4 | Obese cynomolgus monkeys | – | – | Decrease TG- increase adiponectin | Decreases Body Weight and Food Intake | Saswata Talukdar (34) | PF-05231023 |
| 5 | Obese/overweight humans withT2DM | – | – | Decrease TG and LDL- increase HDL and adiponectin | Decrease body weight | Saswata Talukdar (34) | PF-05231023 |
| 6 | Obese and T2DMpatients | – | – | Decrease in LDL, TG and increase in HDL and adiponectin | Decrease body weight | Gaich G,2013 (101) | LY2405319 |
| 7 | Diet-induced obese (DIO) mice | – | – | Decrease plasma glucose | Decrease body weight | Kharitonenkov et al. (102) | LY2405319 |
| 8 | Patients with biopsy-confirmed NASH | Significant decrease in absolute hepatic fat fraction | Decrease Pro-C3 | Decrease ALT, AST, TG and LDL- increase HDL and adiponectin | No substantial changes in bodyweight | Sanyal et al. (12) | Pegbelfermin |
| 9 | Patients with obesity and T2DM | – | Decrease Pro-C3 | Decrease TG, increase in HDL and adiponectin | No statistically significant decrease in weight | Charles et al. (103) | Pegbelfermin |
| 10 | Patients with NASH | Significant reduction in hepatic fat fraction | Decrease Pro-C3 | Decrease in AST, ALT, ALP, HbA1C, fasting glucose, cholesterol and LDL- increase HDL and adiponectin | Decrease body weight | Harrison et al. (104) | Efruxifermin |
| 11 | Patients with obesity and NAFLD | Decrease hepatic fat content | Decrease Pro-c3 | Decrease TG, LDL- increase HDL and adiponectin | Transient body weight reduction | Negi et al. (105) | BFKB8488A |
| 12 | Obese cynomolgus monkey | – | – | Increase adiponetin | Decrease weight and food intake | Baruch et al. (44) | BFKB8488A |
| 13 | Insulin resistant, obese subjects with increased liver fat | Decrease hepatic fat content | – | Decrease HbA1C, TG, LDL- increase HDL | – | Depaoli et al. (106) | MK-3655, |
| 14 | Obese and mildly hypertriglyceridemic adults | Decrease hepatic fat content | Decrease Pro-C3 and improved liver fibrosis | Decrease in AST, ALT, ALP, cholesterol and LDL-increase HDL | – | Rader et al. (107) | LLF580 |
| 15 | Mice on methionine and choline-deficient diets | Decrease hepatic TG | Decrease inflammation and fibrosis | Decrease in ALT and free fatty acid | No change in body weight | Fisher et al. (108) | Recombinant FGF21 |